Crinetics Pharmaceuticals, Inc.
CRNX
株式のランク
#2230
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
株価
$84.95
最終同期: 2026-09-01
時価総額
$9.00B
変化（1日）
0.00%
変化（1年）
98.25%
国
US
取引 Crinetics Pharmaceuticals, Inc. (CRNX)
カテゴリー
Healthcare
Crinetics Pharmaceuticals, Inc.（CRNX）の株式分割履歴
Crinetics Pharmaceuticals, Inc.株（シンボル：CRNX）は合計で0回の株式分割を実施しました。
最新の株式分割はOct 21, 2026に行われました。
Oct 21, 2026より前に購入されたCRNX株は、現在0CRNX株に相当します。
最新の株式分割はOct 21, 2026に行われました。
Oct 21, 2026より前に購入されたCRNX株は、現在0CRNX株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 提供された日付のデータは十分ではありません。 | |||
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
